FOI release
Complaints Regarding Pharmacies Advertising Weight-Loss Medicines
Some or all of the information requested was not provided because we determined that the cost to do so would exceed the appropriate limit.
Case reference FOI2026/00997
Received 7 September 2026
Published 9 October 2026
Request
Under the Freedom of Information Act, I would like to request the following information within the 20 days timeframe: The number of complaints you have had on pharmacies breaking advertising laws by advertising the below named medicines for weight loss directly to the public over the past two years (July 2024 to July 2026), giving figures by quarters. I would also like the name and address of the pharmacy a complaint has been made against. The drugs I would like information on are: • Wegovy (semaglutide) – subcutaneous injection • Wegovy (semaglutide) – tablet • Mounjaro (tirzepatide) – subcutaneous injection NB: Please supply the number of complaints made for each of the three medicines mentioned above, unless this work would exceed the appropriate time limit outlined in Section 12 of the FOI Act, in which case it would be acceptable to provide the number of complaints as a total across all three medicines. I am happy for you to supply the information in a way that is most convenient for you but is also as clear as possible.
Response
See attached
Documents
This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.
You can browse our other responses or make a new FOI request.